MRI diagnostic for differentiating low-grade bladder cancers

MRI diagnostic for differentiating low-grade bladder cancers

(HealthDay)—Magnetic resonance (MR) imaging is accurate in differentiating T1 or lower tumors from T2 or higher tumors among patients with bladder cancer, according to a review published in the February issue of Radiology.

Li Huang, M.D., Ph.D., from Sun Yat-Sen University in Guangzhou, China, and colleagues conducted a systematic literature review to identify studies evaluating the of MR imaging for differentiating stage T1 or lower tumors from stage T2 or higher tumors in patients with bladder cancer. Additionally, studies assessing the influence of different imaging protocols in patients with bladder cancer were examined.

The researchers identified 17 studies totaling 1,449 patients with . Across studies, the pooled sensitivity of MR imaging was 0.90 and the specificity was 0.88 for differentiating tumors staged T1 or lower from those staged T2 or higher. Sensitivity (0.92) and specificity (0.96) were improved with diffusion-weighted imaging and use of higher field strengths (3 T).

"Our meta-analysis shows and specificity for MR imaging to differentiate T1 or lower tumors from T2 or higher tumors before surgery and that a 3.0-T device combined with diffusion-weighted imaging had the highest sensitivity and specificity in all studies," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Radiology

Copyright © 2018 HealthDay. All rights reserved.

Citation: MRI diagnostic for differentiating low-grade bladder cancers (2018, January 29) retrieved 26 April 2024 from https://medicalxpress.com/news/2018-01-mri-diagnostic-differentiating-low-grade-bladder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Active surveillance feasible for small, low-grade bladder cancer

4 shares

Feedback to editors